Progress in the US With Biosimilars, but Opportunities Remain

Managed Care Cast

Last year was a big year for biosimilars in the United States with the number of FDA-approved biosimilars nearly doubling and major policy and regulatory developments taking place in 2018. Kelly Davio, senior editor of AJMC's The Center for Biosimilars, highlights recent progress, how the US market compares with Europe, and what remains to be seen. Read more: The Center for Biosimilars: https://www.centerforbiosimilars.com/ Stakeholders Weigh In on the Key Biosimilar Developments of 2018: https://www.centerforbiosimilars.com/news/stakeholders-weigh-in-on-the-key-biosimilar-developments-of-2018 Coherus Confirms That It Has Launched Its Pegfilgrastim Biosimilar, Udenyca: https://www.centerforbiosimilars.com/news/coherus-confirms-that-it-has-launched-its-pegfilgrastim-biosimilar-udenyca FDA Releases Biosimilar Action Plan: https://www.centerforbiosimilars.com/news/fda-releases-biosimilar-action-plan Pfizer Launches Epoetin Alfa Biosimilar, Retacrit, at 33.5% Discount to Reference Epogen: https://www.centerforbiosimilars.com/news/pfizer-launches-epoetin-alfa-biosimilar-retacrit-at-335-discount-to-reference-epogen Pfizer Becomes Latest to Settle With AbbVie Over Humira: https://www.centerforbiosimilars.com/news/pfizer-becomes-latest-to-settle-with-abbvie-over-humira